Literature DB >> 15476221

Interferon-alpha-inducible proteins are novel autoantigens in murine lupus.

Wolfgang Hueber1, Defu Zeng, Samuel Strober, Paul J Utz.   

Abstract

OBJECTIVE: To investigate the spectrum of B cell autoimmunity in the recently described anti-CD1-autoreactive T cell receptor (TCR)-transgenic murine lupus-like (CD1 lupus-like) model.
METHODS: Lethally irradiated BALB/c/nu/nu mice were injected intravenously with donor BALB/c bone marrow and spleen cells expressing TCRalpha and TCRbeta transgenes that recognize CD1d. Sera from adoptive host animals that developed lupus (i.e., CD1 lupus mice) were collected at serial time points and analyzed by Western blotting and immunoprecipitation, using protein extracts prepared from NIH3T3 mouse fibroblasts and EL-4 lymphocytes, respectively. Sera obtained from older animals in several models of spontaneous lupus (NZB/NZW, MRL++, and MRL/lpr mice), unmanipulated BALB/c/nu/nu mice, and normal BALB/c mice were used as controls.
RESULTS: Analyses demonstrated that the prominent targets of autoantibodies in the CD1 lupus-like model are interferon-alpha (IFNalpha)-inducible antigens. Biochemical and serologic characterizations identified one antigen as belonging to the interferon-inducible 202 (Ifi202) subfamily of proteins within the Ifi200 family, and a second antigen as a member of the 70-kd heat-shock protein family. Autoantibodies directed against these antigens were rapidly produced at an early stage of disease. Anti-p50 autoantibodies were present in sera from 7 (78%) of 9 CD1 lupus mice that developed severe kidney disease.
CONCLUSION: IFNalpha-inducible proteins represent a novel class of autoantigens in murine lupus, and the findings suggest additional roles for IFNalpha in this disease. Since Ifi202 autoantigens are encoded by the murine non-major histocompatibility complex lupus-susceptibility gene locus Ifi202, these data provide a link between recent advances in lupus genetics and the formation of autoantibodies. Copyright 2004 American College of Rheumatology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15476221     DOI: 10.1002/art.20508

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  5 in total

Review 1.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  An epistatic effect of the female specific loci on the development of autoimmune vasculitis and antinuclear autoantibody in murine lupus.

Authors:  M-C Zhang; N Misu; H Furukawa; Y Watanabe; M Terada; H Komori; T Miyazaki; M Nose; M Ono
Journal:  Ann Rheum Dis       Date:  2005-09-08       Impact factor: 19.103

Review 3.  Vicious circle: systemic autoreactivity in Ro52/TRIM21-deficient mice.

Authors:  Silvia Bolland; Adolfo Garcia-Sastre
Journal:  J Exp Med       Date:  2009-07-27       Impact factor: 14.307

Review 4.  Autoantibodies in systemic lupus erythematosus.

Authors:  Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2011-12-23       Impact factor: 3.651

5.  Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.

Authors:  Jeffrey M Riggs; Richard N Hanna; Bhargavi Rajan; Kamelia Zerrouki; Jodi L Karnell; Divya Sagar; Inna Vainshtein; Erika Farmer; Kimberly Rosenthal; Chris Morehouse; Melissa de Los Reyes; Kevin Schifferli; Meina Liang; Miguel A Sanjuan; Gary P Sims; Roland Kolbeck
Journal:  Lupus Sci Med       Date:  2018-04-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.